Literature DB >> 2196554

Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease.

P T Männistö1, S Kaakkola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2196554     DOI： 10.1111/j.1600-0773.1990.tb00756.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN： 0901-9928


× No keyword cloud information.
  27 in total

1.  Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.

Authors:  M Yamamoto; M Yokochi; S Kuno; Y Hattori; Y Tsukamoto; H Narabayashi; H Tohgi; Y Mizuno; H Kowa; N Yanagisawa; I Kanazawa
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 2.  New directions in the drug treatment of Parkinson's disease.

Authors:  J L Montastruc; O Rascol; J M Senard
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

3.  Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.

Authors:  T Keränen; A Gordin; M Karlsson; K Korpela; P J Pentikäinen; H Rita; E Schultz; L Seppälä; T Wikberg
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

4.  Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease.

Authors:  P T Ménnistó
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

5.  NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells.

Authors:  Seema Singh; Muhammad Zahid; Muhammad Saeed; Nilesh W Gaikwad; Jane L Meza; Ercole L Cavalieri; Eleanor G Rogan; Dhrubajyoti Chakravarti
Journal:  J Steroid Biochem Mol Biol       Date:  2009-07-21       Impact factor: 4.292

6.  Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat.

Authors:  P T Männistö; P Tuomainen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-10       Impact factor: 3.000

7.  Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.

Authors:  E Nissinen; I B Lindén; E Schultz; P Pohto
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-09       Impact factor: 3.000

8.  Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.

Authors:  J Dingemanse; K Jorga; G Zürcher; M Schmitt; G Sedek; M Da Prada; P Van Brummelen
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

Review 9.  [Pharmacological treatment of motor symptoms in Parkinson's diseases].

Authors:  W H Jost
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

10.  Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice.

Authors:  A Fredriksson; T Archer
Journal:  J Neural Transm Gen Sect       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.